---
title: "Sihuan Pharmaceutical Expects Significant Profit Growth for 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275478371.md"
datetime: "2026-02-10T14:54:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275478371.md)
  - [en](https://longbridge.com/en/news/275478371.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275478371.md)
---

# Sihuan Pharmaceutical Expects Significant Profit Growth for 2025

Sihuan Pharmaceutical Holdings Group Ltd. has issued a positive profit alert for the year, indicating a significant improvement in business performance. The company highlighted that its innovative drug business has entered a harvest period, with subsidiaries Xuanzhu Biopharm and Huisheng Biopharm achieving notable year-on-year revenue growth. Sihuan Pharmaceutical also reported a transition from an investment phase to a revenue-generating phase in its innovative drug segment, leading to a marked enhancement in its profit structure. Additionally, the company noted substantial equity appreciation gains following the successful spin-off listing of Xuanzhu Biopharm and multiple rounds of share repurchases, which have strengthened its financial position and driven breakthroughs in profitability. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260210-12021262), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [00460.HK](https://longbridge.com/en/quote/00460.HK.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [02575.HK](https://longbridge.com/en/quote/02575.HK.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)

## Related News & Research

- [Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan](https://longbridge.com/en/news/282442087.md)
- [Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori](https://longbridge.com/en/news/282752451.md)
- [Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision](https://longbridge.com/en/news/279271433.md)
- [Verde Developing Environmental Product Declaration (EPD) For Its Engineered Biochar in Road Materials | VRDR Stock News](https://longbridge.com/en/news/282847325.md)
- [Anthropic adds Novartis CEO Vas Narasimhan to its board](https://longbridge.com/en/news/282719936.md)